TargED Biopharmaceuticals is focused on developing innovative biological drugs aimed at improving the treatment of thrombosis, a condition responsible for millions of deaths annually. The company's lead product, TGD001, utilizes a unique approach by employing small antibodies known as VHHs to deliver enzymes directly to thrombotic sites. This targeted enzyme delivery system facilitates localized thrombolysis, which is the breakdown of blood clots, thereby enhancing the efficacy of treatment for various thrombotic disorders, including Immune Thrombotic Thrombocytopenic Purpura (iTTP) and Acute Ischemic Stroke (AIS).

The technology behind TGD001 is designed to accelerate thrombolysis across different types of thrombosis, regardless of the clot's composition. By focusing on targeted delivery, TargED aims to improve patient outcomes and address the significant health burden posed by thrombotic conditions. The company is currently in the preclinical validation stage for TGD001, with ambitions to advance its development through various phases of clinical trials, ultimately striving to provide effective therapies for patients suffering from thrombosis.

Netherlands

TargED started in September 2018 and is currently developing one biopharmaceutical product: MICROLYSE. MICROLYSE enzymatically breaks down blood clots in small blood vessels (i.e. the microvasculature), for which to date, no specific treatment exists. TargED pursues to receive market authorization for an orphan disease named Thrombotic Thrombocytopenic Purpura (TTP) that is characterized by life threatening attacks of microvascular thrombosis. However, MICROLYSE has the capacity to target all forms of microvascular thrombosis and could also be applied in early-stage macrovascular thrombosis as seen in heart attacks and stroke.

TargED Biopharmaceuticals

Company Details